FI973023A - Liikakasvusairauksien yhdistetty terapeuttinen hoito - Google Patents

Liikakasvusairauksien yhdistetty terapeuttinen hoito Download PDF

Info

Publication number
FI973023A
FI973023A FI973023A FI973023A FI973023A FI 973023 A FI973023 A FI 973023A FI 973023 A FI973023 A FI 973023A FI 973023 A FI973023 A FI 973023A FI 973023 A FI973023 A FI 973023A
Authority
FI
Finland
Prior art keywords
therapeutic treatment
combined therapeutic
obesity disorders
obesity
disorders
Prior art date
Application number
FI973023A
Other languages
English (en)
Swedish (sv)
Other versions
FI973023A0 (fi
FI119911B (fi
Inventor
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI973023A publication Critical patent/FI973023A/fi
Publication of FI973023A0 publication Critical patent/FI973023A0/fi
Application granted granted Critical
Publication of FI119911B publication Critical patent/FI119911B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI973023A 1995-01-17 1997-07-16 Liikakasvusairauksien yhdistetty terapeuttinen hoito FI119911B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
FR9500436 1995-01-17
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives
FR9600056 1996-01-12

Publications (3)

Publication Number Publication Date
FI973023A true FI973023A (fi) 1997-07-16
FI973023A0 FI973023A0 (fi) 1997-07-16
FI119911B FI119911B (fi) 2009-05-15

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973023A FI119911B (fi) 1995-01-17 1997-07-16 Liikakasvusairauksien yhdistetty terapeuttinen hoito

Country Status (21)

Country Link
US (3) US6262032B1 (fi)
EP (1) EP0800399B1 (fi)
JP (3) JP4580469B2 (fi)
KR (1) KR100385266B1 (fi)
AT (1) ATE222109T1 (fi)
AU (1) AU716364B2 (fi)
BR (1) BR9606969A (fi)
CA (1) CA2209771C (fi)
CZ (1) CZ298710B6 (fi)
DE (1) DE69622989T2 (fi)
DK (1) DK0800399T3 (fi)
ES (1) ES2180729T3 (fi)
FI (1) FI119911B (fi)
FR (1) FR2729295A1 (fi)
HU (1) HU229484B1 (fi)
MX (1) MX9704490A (fi)
NO (1) NO325418B1 (fi)
PT (1) PT800399E (fi)
SI (1) SI0800399T1 (fi)
SK (1) SK283989B6 (fi)
WO (1) WO1996022101A1 (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CN1816564B (zh) * 2003-06-30 2010-11-24 洛桑大学 能选择性杀伤癌细胞的RasGAP衍生肽
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
WO2005061001A1 (ja) * 2003-12-24 2005-07-07 Locomogene, Inc. 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2634833B2 (ja) * 1986-03-28 1997-07-30 ボード オブ トラステイーズ オブ ユニヴアーシテイ オブ イリノイ ヒト細胞における複数薬剤耐性に関連するｄｎａ配列を含むクローンの組成および方法
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
US6262032B1 (en) 2001-07-17
DE69622989T2 (de) 2002-12-05
FR2729295B1 (fi) 1997-02-28
JPH10512559A (ja) 1998-12-02
SK283989B6 (sk) 2004-07-07
US7884082B2 (en) 2011-02-08
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
NO325418B1 (no) 2008-04-21
HUP9802423A2 (hu) 1999-02-01
WO1996022101A1 (fr) 1996-07-25
DK0800399T3 (da) 2002-12-02
NO973197D0 (no) 1997-07-09
KR100385266B1 (ko) 2005-09-07
CZ298710B6 (cs) 2008-01-02
JP4580469B2 (ja) 2010-11-10
CZ226297A3 (en) 1997-10-15
ATE222109T1 (de) 2002-08-15
EP0800399A1 (fr) 1997-10-15
NO973197L (no) 1997-07-09
JP2012036201A (ja) 2012-02-23
HU229484B1 (en) 2014-01-28
DE69622989D1 (de) 2002-09-19
SI0800399T1 (en) 2002-12-31
BR9606969A (pt) 1997-11-04
SK95797A3 (en) 1997-12-10
FI973023A0 (fi) 1997-07-16
PT800399E (pt) 2002-12-31
FR2729295A1 (fr) 1996-07-19
CA2209771A1 (fr) 1996-07-25
EP0800399B1 (fr) 2002-08-14
KR19980701449A (ko) 1998-05-15
US20010021395A1 (en) 2001-09-13
AU716364B2 (en) 2000-02-24
US20050209177A9 (en) 2005-09-22
JP5031921B2 (ja) 2012-09-26
JP2008133291A (ja) 2008-06-12
HUP9802423A3 (en) 2000-11-28
FI119911B (fi) 2009-05-15
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
FI973023A (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
HUP0103839A3 (en) Use of certain drugs for treating nerve root injury
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
MXPA02005667A (es) Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
IL116733A0 (en) The use of sertraline to treat cancer patients
EP0835662A3 (en) A drug for the treatment of cancer
GR3033061T3 (en) Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
TR199801887A2 (xx) Bir Na+/H+ - de�i�tiricisi inhibit�r�.
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
GEP19991781B (en) Means for Treatment of Prostate Diseases
UA30329A (uk) Спосіб лікування хронічних запальних захворювань придатків матки
EA200001091A1 (ru) Способ лечения заболеваний, связанных с образованием конкрементов
HU9500304V0 (en) Therapeutic aid for treatment of foot

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119911

Country of ref document: FI

MA Patent expired